Abstract
Objective To explore the relationship between blood pressure and the risk of acute myocardial infarction (AMI) in Chinese adults.
Methods This prospective cohort study included 26,794 participants which were recruited from 60 surveillance sites in 2010 China Chronic Disease Risk Factor Surveillance and followed-up survey was conducted from 2016 to 2017. Data were collected by questionnaires, physical measurements and laboratory tests. Blood pressure was grouped by systolic blood pressure and diastolic blood pressure, and cox proportional hazards regression models were used to analyze the relationship between blood pressure and risk of AMI.
Results A total of 256 AMI events occurred among 160,386.38 person-years follow-up and the incidence of AMI was 159.6/100,000 person-years. After adjusting for age, sex, income, education, marital status, physical activity, drinking, abdominal obesity, BMI, dyslipidemia and diabetes, compared with normotension group, the risk of AMI onset was increased by 61% (HR=1.61, 95% CI: 1.17∼2.21), 60% (HR=1.60, 95% CI: 1.17∼2.20), 84% (HR=1.84, 95% CI: 1.26∼2.68) and 120% (HR=2.20, 95% CI: 1.43∼3.38) in systolic diastolic hypertension(SDH), hypertension grade 1(mild), hypertension grade 2(moderate), hypertension grade 3(severe), respectively. In addition, after adjusting for relevant factors, the relationship between hypertension and the risk of AMI may be influenced by abdominal obesity, diabetes and lack of physical activity.
Conclusions The incidence of AMI appears to be considerable among Chinese adults and hypertension is an independent risk factor for its onset. The risk of AMI is higher in participants with more severe hypertension.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by National Key Research and Development Program of China (2018YFC1313900, 2018YFC1313904). The funders were not involved in research design, data collection and analysis, decisions to publish, and prepare manuscripts.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study had been passed the review of the Ethics Review Committee of the National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention (approval number: 201524B)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† Joint first authors
Data Availability
Data are available and can be obtained by contacting the corresponding author.
